Tofacitinib as induction and maintenance therapy for ulcerative colitis
N Engl J Med. 2017 May 4;376(18):1723-1736. DOI 10.1056/NEJMoa1606910
Tofacitinib, at a dose of 10 mg twice daily, was more effective than placebo for induction of remission and mucosal healing in patients with moderately to severely active ulcerative colitis. Furthermore, maintenance therapy with tofacitinib, at a dose of either 5 mg or 10 mg twice daily, was more effective than placebo in sustaining remission and mucosal healing.
Investigators aimed to evaluate the efficacy of tofacitinib as induction and maintenance therapy. They discovered that onset of action was rapid, with significant improvement in the partial Mayo score observed at 2 weeks.
Keywords:
